Plain-English translation of NCT06775470 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →This research study is examining how different changes in the BRCA1 and BRCA2 genes affect how well ovarian cancer patients respond to treatment — particularly to a class of drugs called PARP inhibitors. Researchers want to understand whether certain gene variations predict which patients will benefit most from this medication and what their long-term survival might look like.
Right now, doctors use BRCA gene testing to decide which ovarian cancer patients should receive PARP inhibitors. However, recent research suggests that not all gene changes that seem important for cancer risk actually predict whether this treatment will work. This study aims to clarify which specific gene changes truly matter for treatment response, so doctors can better personalize care for future patients.
You likely qualify if…
You likely don't qualify if…
This is an observational study, meaning researchers will review your medical records, treatment history, and existing BRCA test results — they won't ask you to take any new medications or undergo new procedures. The study team will look at how your cancer responded to the treatment you already received and track your health outcomes over time to understand the connection between your specific gene changes and your treatment response.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Italy
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment target
~300 participants
Started
July 2022
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Sex
Female only
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Daniela Turchetti, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.